Article
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
The Lancet. Oncology - 1 Oct 2015
Grob Jean Jacques, Amonkar Mayur M, Karaszewska Boguslawa, Schachter Jacob, Dummer Reinhard, Mackiewicz Andrzej, Stroyakovskiy Daniil, Drucis Kamil, Grange Florent, Chiarion-Sileni Vanna, Rutkowski Piotr, Lichinitser Mikhail, Levchenko Evgeny, Wolter Pascal, Hauschild Axel, Long Georgina V, Nathan Paul, Ribas Antoni, Flaherty Keith, Sun Peng, Legos Jeffrey J, McDowell Diane Opatt, Mookerjee Bijoyesh, Schadendorf Dirk, Robert Caroline
Abstract excerpt
BACKGROUND: In the COMBI-v trial, patients with previously untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were treated with the combination of dabrafenib and trametinib had significantly longer overall and progression-free survival than those treated with vemurafenib alone. Here, we present the effects of treatments on health-related quality of life (HRQoL), an exploratory...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.